# Novel Double Target Therapy Combined With Chemotherapy in First-line Treatment of HER2+ Breast Cancer, MA-BC-II-038

> **NCT05429294** · PHASE2 · UNKNOWN · sponsor: **First Affiliated Hospital Xi'an Jiaotong University** · enrollment: 209 (estimated)

## Conditions studied

- HER2-positive Breast Cancer

## Interventions

- **DRUG:** Pyrotinib

## Key facts

- **NCT ID:** NCT05429294
- **Lead sponsor:** First Affiliated Hospital Xi'an Jiaotong University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-06-01
- **Primary completion:** 2024-05-31
- **Final completion:** 2024-10-30
- **Target enrollment:** 209 (ESTIMATED)
- **Last updated:** 2022-06-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05429294

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05429294, "Novel Double Target Therapy Combined With Chemotherapy in First-line Treatment of HER2+ Breast Cancer, MA-BC-II-038". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT05429294. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*